# Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides

> **NCT00562575** · PHASE2 · COMPLETED · sponsor: **Response Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** SLx-4090
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00562575
- **Lead sponsor:** Response Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562575, "Evaluation of Safety and Effects of SLx-4090 After Dosing for 14 Days in Subjects With High Triglycerides". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00562575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*